Delving into the Latest Updates on QLS1209 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

PKMYT1

Action

inhibitors

Mechanism

PKMYT1 inhibitors(protein kinase, membrane associated tyrosine/threonine 1 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Qilu Pharmaceutical Co., Ltd.

Active Organization

Qilu Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Start Date01 Apr 2025

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

100 Clinical Results associated with QLS1209

Login to view more data

100 Translational Medicine associated with QLS1209

Login to view more data

100 Patents (Medical) associated with QLS1209

Login to view more data

100 Deals associated with QLS1209

Login to view more data